ClassID:

21484

A61K49/108 - CPC Classification

Classification description:

Preparations for testing; Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier; Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA

Recent Application in this class:
#1
20260091146
2026-04-02

PROCESS FOR PRODUCING A CONTRAST AGENT

#2
20260087710
2026-03-26

GENERATION OF ARTIFICIAL CONTRAST-ENHANCED RADIOLOGICAL IMAGES

#3
20260087709
2026-03-26

GENERATION OF SYNTHETIC RADIOLOGICAL IMAGES

#4
20260083864
2026-03-26

CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING

#5
20260077069
2026-03-19

COMBINATIONS OF CONTRAST AGENTS

#6
20250378594
2025-12-11

GENERATING SYNTHETIC REPRESENTATIONS

#7
20250281652
2025-09-11

TARGETED CONTRAST AGENTS FOR MRI OF AMYLOID DEPOSITION

#8
20250230135
2025-07-17

METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY

#9
20250191242
2025-06-12

GENERATING SYNTHETIC REPRESENTATIONS

#10
20250152753
2025-05-15

FORMULATION OF CONTRAST MEDIA AND PROCESS OF PREPARATION THEREOF

#11
20250135042
2025-05-01

Perfluorocarbon-Containing Contrast Agent for Use in MRI Imaging of Body Cavities

#12
20250064988
2025-02-27

MRI-AGENT LOADED PLATELET COMPOSITIONS AND METHODS OF PREPARING AND USING THE SAME

#13
20250045926
2025-02-06

DETECTION OF ARTIFACTS IN SYNTHETIC IMAGES

#14
20250041460
2025-02-06

LANTHANIDE-BASED CONTRAST AGENTS HAVING IMPROVED STABILITY AND METHODS FOR THEIR PRODUCTION AND PURIFICATION

#15
20240404255
2024-12-05

GENERATION OF ARTIFICIAL CONTRAST-ENHANCED RADIOLOGICAL IMAGES

#16
20240399000
2024-12-05

GADOLINIUM-BASED COMPOUND AND MRI CONTRAST AGENT COMPRISING SAME

#17
20240366803
2024-11-07

LANTHANIDE COMPLEX FORMULATIONS

#18
20240366802
2024-11-07

GADOLINIUM BEARING PCTA-BASED CONTRAST AGENTS

#19
20240358864
2024-10-31

LANTHANIDE COMPLEX FORMULATIONS

#20
20240285808
2024-08-29

MOLECULAR PROBES FOR IN VIVO DETECTION OF ALDEHYDES

#21
20240277874
2024-08-22

FLUORESCENCE-MAGNETIC RESONANCE DUAL-MODALITY CONTRAST AGENT, PREPARATION METHOD THEREFOR AND USE THEREOF

#22
20240252690
2024-08-01

Formulation of contrast media and process of preparation thereof

#23
20240189459
2024-06-13

METASTABLE-FREE LANTHANIDE BASED CONTRAST AGENTS AND METHOD

#24
20230414792
2023-12-28

PLASTIC CONTAINERS

#25
20230405153
2023-12-21

FIBROBLAST ACTIVATION PROTEIN-TARGETED MAGNETIC RESONANCE IMAGING AGENTS, COMPOSITIONS, AND METHODS OF USE

#26
20230398238
2023-12-14

TARGETED CONTRAST AGENTS FOR MRI OF ALPHA-SYNUCLEIN DEPOSITION

#27
20230390394
2023-12-07

Bismuth-Gadolinium Nanoparticles

#28
20230248851
2023-08-10

PROCEDURE FOR OBTAINING GADOTERATE MEGLUMINE FROM HIGH-PURITY TETRAXETAN (DOTA) AND ITS USE IN THE PREPARATION OF INJECTABLE GALENICAL FORMULATIONS

#29
20230233714
2023-07-27

NOVEL GADOLINIUM-BASED COMPOUND, METHOD FOR PRODUCING SAME, AND MRI CONTRAST AGENT CONTAINING SAME

#30
20230201381
2023-06-29

Polydopamine decorated tobacco mosaic theranostic virus nanoparticles

#31
20230149569
2023-05-18

MULTIFUNCTIONAL COMPOUNDS FOR USE IN MEDICAL IMAGING AND THERAPY

#32
20230094602
2023-03-30

NOVEL GADOLINIUM-BASED COMPOUND, PREPARATION METHOD THEREFOR, AND MRI CONTRAST AGENT CONTAINING SAME

#33
20230025866
2023-01-26

NOVEL MANUFACTURING PROCESS FOR GADOLINIUM COMPLEXES

#34
20220387634
2022-12-08

REDUCED METASTABLE COMPLEX MACROCYCLIC CONTRAST AGENTS

#35
20220380386
2022-12-01

NOVEL GADOLINIUM-BASED COMPOUND, METHOD FOR PRODUCING SAME, AND MRI CONTRAST AGENT CONTAINING SAME

#36
20220370646
2022-11-24

PHARMACEUTICAL COMPOSITIONS OF GD-BASED CONTRAST AGENTS

#37
20220354971
2022-11-10

Lanthanide complex formulations

#38
20220265868
2022-08-25

Targeted contrast agents for MRI of alpha-synuclein deposition

#39
20220211881
2022-07-07

Coated plant virus imaging agents

#40
20220211880
2022-07-07

IMAGING WITH LIPOSOME-BASED CONTRAST AGENTS BASED ON MODULATION OF MEMBRANE WATER PERMEABILITY

#41
20220211879
2022-07-07

SOLVENT FREE GADOLINIUM CONTRAST AGENTS

#42
20220202964
2022-06-30

HEPARANASE COMPOUNDS AND METHODS OF USE

#43
20220135529
2022-05-05

METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY

#44
20220080058
2022-03-17

Reduced metastable complex macrocyclic contrast agents

#45
20220079984
2022-03-17

METHOD FOR TREATING CANCER WITH KIDNEY PROTECTION

#46
20220062444
2022-03-03

Pharmaceutical compositions comprising Gd-complexes and polyarylene additives

#47
20220023445
2022-01-27

TARGETED CONTRAST AGENTS FOR MRI OF AMYLOID DEPOSITION

#48
20220008562
2022-01-13

Formulation of contrast media and process of preparation thereof

#49
20210252170
2021-08-19

TARGETED CONTRAST AGENTS FOR MRI OF ALPHA-SYNUCLEIN DEPOSITION

#50
20210244831
2021-08-12

Polydopamine decorated tobacco mosaic theranostic virus nanoparticles

#51
20210236662
2021-08-05

Targeted contrast agents for MRI of amyloid deposition

#52
20210196840
2021-07-01

Gadolinium bearing PCTA-based contrast agents

#53
20210100920
2021-04-08

METHODS AND AGENTS FOR THE DETECTION AND TREATMENT OF CANCER

#54
20210069355
2021-03-11

Plastic containers

#55
20210052748
2021-02-25

Compound, antiinflammatory drug comprising the compound and cyclooxygenase-2 inhibitor comprising the compound

#56
20210024500
2021-01-28

Dimeric contrast agents

#57
20200405885
2020-12-31

MAGNETIC RESONANCE IMAGING (MRI) CONTRAST AGENTS AND USE THEREOF

#58
20200397924
2020-12-24

PREPARATION METHOD OF INTERMEDIATE OF GADOLINIUM-BASED IONIC CONTRAST AGENT AND USE THEREOF

#59
20200390910
2020-12-17

PROCESS FOR PRODUCING A CONTRAST AGENT

#60
20200384131
2020-12-10

Coated plant virus imaging agents

#61
20200331893
2020-10-22

DIMERIC CONTRAST AGENTS

#62
20200325108
2020-10-15

Contrast agents

#63
20200290982
2020-09-17

METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY

#64
20200222560
2020-07-16

Development of injectable fiducial markers for image guided radiotherapy with dual MRI and CT visibility

#65
20200181098
2020-06-11

Gadobutrol intermediate and gadobutrol production method using same

#66
20200155712
2020-05-21

Lanthanide complex formulations

#67
20200108155
2020-04-09

Ultrafine nanoparticles as multimodal contrast agent

#68
20200055020
2020-02-20

Metal-organic frameworks for the adsorption and catalytic transformations of carbon dioxide

#69
20200046859
2020-02-13

MODIFIED MRI CONTRAST AGENTS AND USES THEREOF

#70
20200017453
2020-01-16

Dimeric contrast agents

#71
20200000915
2020-01-02

Bismuth-gadolinium nanoparticles

#72
20190365933
2019-12-05

Solvent-free gadolinium contrast agents

#73
20190345142
2019-11-14

Dimeric contrast agents

#74
20190321494
2019-10-24

POLYMALIC ACID BASED NANOCONJUGATES FOR IMAGING

#75
20190307892
2019-10-10

TARGETED DRUG DELIVERY AND THERAPEUTIC METHODS USING APO-E MODIFIED LIPID NANOPARTICLES

#76
20190292206
2019-09-26

Gadolinium complex, method for synthesis of the gadolinium complex, and MRI contrast agent including the gadolinium complex

#77
20190269805
2019-09-05

SOLVENT-FREE GADOLINIUM CONTRAST AGENTS

#78
20190209713
2019-07-11

CEST systems exhibiting a concentration independent responsiveness

#79
20190142977
2019-05-16

Gadolinium-based contrast agents for sensitive detection of Znwith MRI

#80
20190077925
2019-03-14

Process for preparation of beads for imaging

#81
20190060490
2019-02-28

PAMAM dendrimer based CEST imaging agents and uses thereof

#82
20180369427
2018-12-27

Non-nutritive sweeteners and polyols as imaging agents

#83
20180362511
2018-12-20

Dimeric contrast agents

#84
20180362476
2018-12-20

Contrast agents

#85
20180303960
2018-10-25

Combination formulation

#86
20180256758
2018-09-13

Coated plant virus imaging agents

#87
20180238908
2018-08-23

NEURODEGENERATIVE DISORDERS

#88
20180207297
2018-07-26

Plastic containers

#89
20180185521
2018-07-05

Solvent-Free Gadolinium Contrast Agents

#90
20170340757
2017-11-30

Targeted contrast agents comprising a hydrazide functional group

#91
20170266304
2017-09-21

Metal complex formulations

#92
20170258945
2017-09-14

Lanthanide complex formulations

#93
20170258944
2017-09-14

Formulations of metal complexes

#94
20170246326
2017-08-31

Modular Imaging Agents Containing Amino Acids and Peptides

#95
20170216462
2017-08-03

Method for producing a liquid pharmaceutical preparation

#96
20170209602
2017-07-27

Method and compositions for orally administered contrast agents for MR imaging

#97
20170189563
2017-07-06

Process for preparing a pharmaceutical formulation of contrast agents

#98
20170106103
2017-04-20

Gadolinium-based contrast agents for sensitive detection of Znwith MRI

#99
20170081298
2017-03-23

Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy

#100
20170074859
2017-03-16

Graphene oxide mediated cellular delivery of gadolinium-labeled molecules

#101
20170008876
2017-01-12

Metal Chelate Compounds for Binding to the Platelet Specific Glycoprotein IIb/IIIa

#102
20170007726
2017-01-12

Process for purifying 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetraacetic acid

#103
20160347831
2016-12-01

Camelid single-domain antibody directed against amyloid beta and methods for producing conjugates thereof

#104
20160331849
2016-11-17

Gadolinium complex comprising DO3A-tranexamic acid conjugate

#105
20160287726
2016-10-06

CATIONIC CONTRAST AGENTS AND METHODS OF USING THE SAME

#106
20160270687
2016-09-22

System and method for quantitative magnetic resonance (MR) analysis using T1 mapping

#107
20160243265
2016-08-25

Method for preparing a pharmaceutical formulation of lanthanide chelate in powder form

#108
20160235868
2016-08-18

PROCESS FOR PREPARING A PHARMACEUTICAL FORMULATION OF CONTRAST AGENTS

#109
20160235867
2016-08-18

Process for preparing a pharmaceutical formulation of contrast agents

#110
20160184459
2016-06-30

CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE

#111
20160168178
2016-06-16

Multimeric dual-modality breast cancer diagnostic agents

#112
20160101196
2016-04-14

Contrast medium formulation and related preparation method

#113
20160051706
2016-02-25

PROCESS FOR PRODUCING A COMPLEX OF A LANTHANIDE WITH A MACROCYCLIC LIGAND

#114
20160045624
2016-02-18

Coated plant virus imaging agents

#115
20160031909
2016-02-04

PORPHYRAZINE OPTICAL AND DUAL OPTICAL/ MR CONTRAST AND THERAPEUTIC AGENTS

#116
20160024030
2016-01-28

Process for producing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid and complexes thereof

#117
20150297761
2015-10-22

PEPTIDIC STRUCTURES INCORPORATING AN AMINO ACID METAL COMPLEX AND APPLICATIONS IN MAGNETIC RESONANCE IMAGING

#118
20150071863
2015-03-12

Lanthanoid complex capsule and particle contrast agents, methods of making and using thereof

#119
20150050217
2015-02-19

Ultrafine nanoparticles as multimodal contrast agent

#120
20150038672
2015-02-05

Modular imaging agents containing amino acids and peptides

#121
20140363376
2014-12-11

Molecular design toward dual-modality probes for radioisotope-based imaging (PET or SPECT) and MRI

#122
20140343402
2014-11-20

Composition comprising acetic anhydride and a gadolinium complex, and method for the use in hyperpolarisation in MRI analysis

#123
20140171627
2014-06-19

Multimeric biotinidase resistant multimodality probes

#124
20140073780
2014-03-13

Multimeric dual-modality breast cancer diagnostic agents

#125
20140065076
2014-03-06

CONTAINER WITH CONCENTRATED SUBSTANCE AND METHOD OF USING THE SAME

#126
20140065075
2014-03-06

TARGETED CONTRAST AGENTS AND USES THEREOF

#127
20140058072
2014-02-27

Multimeric peptidomimetic fibrosis specific dual-modality probes

#128
20130302258
2013-11-14

MRI contrast agents

#129
20130142735
2013-06-06

In Vivo Mitochondrial Labeling Using Positively-CHarged Nitroxide Enhanced and Gadolinum Chelate Enhanced Magnetic Resonance Imaging

#130
20120294809
2012-11-22

Lanthanoid complex capsule and particle contrast agents, methods of making and using thereof

#131
20120082624
2012-04-05

Method for preparing a pharmaceutical formulation of lanthanide chelate in powder form

#132
20110129425
2011-06-02

Process for preparing a pharmaceutical formulation of contrast agents

#133
20090214437
2009-08-27

In vivo mitochondrial labeling using positively-charged nitroxide enhanced and gadolinium chelate enhanced magnetic resonance imaging

#134
20090208421
2009-08-20

Process for preparing a pharmaceutical formulation of contrast agents